Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$37.54 USD

37.54
2,702,108

+1.05 (2.88%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BAX vs. SYK: Which Stock Should Value Investors Buy Now?

BAX vs. SYK: Which Stock Is the Better Value Option?

Baxter (BAX) to Report Q4 Earnings: What's in the Offing?

Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up

DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.

Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Baxter's (BAX) strong product portfolio.

Why Baxter (BAX) Could Beat Earnings Estimates Again

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Trina Mukherjee headshot

3 Medical Products Stocks Poised to Beat This Earnings Season

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?

Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.

Change Healthcare (CHNG) Q3 Earnings in Line, Revenues Beat

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates

Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.

Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.

AmerisourceBergen (ABC) Q1 Earnings Lag Estimates, Revenues Beat

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe

Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.

NextGen's (NXGN) Integrated Platform to Enhance Tribal Health

NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.

CVS Health (CVS) Hits a 52-Week High: What's Driving It?

Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.

Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus

Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.

Here's Why You Should Invest in Henry Schein (HSIC) Now

Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.

The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips

Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.